| Methods |
Multicenter, double‐blind, placebo‐controlled RCT, 52 weeks |
| Participants |
People of self‐identified black race, age 18 years or over, with active SLE |
| Interventions |
Monthly belimumab 10 mg/kg IV or placebo, plus standard of care |
| Outcomes |
SLE Responder Index response rate with modified SLEDAI‐2K (S2K) scoring for proteinuria, 4‐point reduction in SELENA‐SLEDAI, time to first flare, reduction in prednisone dose by 25%, adverse events |
| Notes |
N = 448 (97% female); study did not achieve primary endpoint but significant improvement in subgroups |
